elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38850801-3E958669-C7E1-4C52-9475-C5DF9AAE32EC
Q38850801-3E958669-C7E1-4C52-9475-C5DF9AAE32EC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38850801-3E958669-C7E1-4C52-9475-C5DF9AAE32EC
Suppression of Poly(rC)-Binding Protein 4 (PCBP4) reduced cisplatin resistance in human maxillary cancer cells.
P2860
Q38850801-3E958669-C7E1-4C52-9475-C5DF9AAE32EC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38850801-3E958669-C7E1-4C52-9475-C5DF9AAE32EC
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1b2d68d79e39fef987f411130fc762a2e5c2d95d
P2860
Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.